NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination with Immunotherapy Vaccine PRGN-2009 in Subjects with Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer

This study is NOT currently recruiting participants.

Summary | Eligibility | Citations | Contacts




Sponsoring Institute

National Cancer Institute (NCI)

Recruitment Detail

Type: Recruitment has not started
Gender: Male & Female
Min Age: 18 Years
Max Age: 120 Years

Referral Letter Required


Population Exclusion(s)

Pregnant Women


Neoadjuvant Chemotherapy;
Oropharynx Cancer;
Human Papillomavirus;
Therapeutic Vaccine

Recruitment Keyword(s)



Squamous cell carcinoma of the head and neck;
Human papillomavirus viruses;
Drug therapy;
Cancer vaccine

Investigational Drug(s)


Investigational Device(s)



Drug: Docetaxel
Drug: Cisplatin
Drug: PRGN-2009

Supporting Site

National Cancer Institute


Throat cancer is a common tumor that can occur in people infected with the human papilloma virus (HPV). Most people with this cancer survive more than 5 years with standard chemotherapy drugs plus radiation. But radiation can cause serious adverse effects. Researchers believe that adding a vaccine (PRGN-2009) to this drug therapy may improve survival without the need for radiation.


To test a study vaccine combined with standard chemotherapy in patients with HPV-associated throat cancers.


People aged 18 years and older with newly diagnosed throat cancer associated with HPV.


Participants will be screened. They will have a physical exam and blood tests. They will have imaging scans and tests of their heart function and hearing. They will provide a sample of tissue from their tumor. A recent sample may be used; if none is available, a new sample will be taken.

All participants will get two common drugs for treating cancer. These drugs are given through a tube attached to a needle inserted into a vein in the arm. Participants will receive these drugs on the first day of three 3-week cycles.

Half of the participants will also get the vaccine. PRGN-2009 is injected under the skin in the arm. They will get these shots 4 times: 7 days before the start of the first cycle and on the 11th day of each cycle.

Participants will have standard surgery to remove their tumors 3 to 6 weeks after completing the study treatment. They will have follow-up visits 3, 6, 12, and 24 months after their surgery.

--Back to Top--



- Histologically or cytologically confirmed surgically resectable newly diagnosed stage I (cT1-2, N0-1) or II (T1-3, N0-2), M0 oropharyngeal squamous cell carcinoma. Note: Pathological report of cancer diagnosis may be from the primary tumor or from a metastatic cervical lymph node.

- History of HPV-positive status determined by a standard-of-care HPV testing. Note: All participants with high-risk HPV serotypes are eligible.

- Age >= 18 years.

- ECOG performance status <= 2.

- Participants who smoke currently must smoke <10 pack years. Note: Former smokers with any pack-year history are eligible if quit smoking >10 years before study treatment initiation.

- Planned for cancer removal surgery per standard of care (SOC) and participant had agreed for the cancer removal surgery.

-- Participants must have adequate organ and marrow function as defined below:

--Absolute neutrophil count (ANC) >= 1.5 (SqrRoot) 10^9/L

--Hemoglobin (Hgb) >= 9.0 g/dL

--Platelet count >= 100 (SqrRoot) 10^9/L

--Creatinine <= 1.2 (SqrRoot) upper limit of normal (ULN) OR calculated creatinine clearance >=55 mL/min/1.73m^2 by Cockcroft-Gault formula

-Total bilirubin <= 1 (SqrRoot) ULN.

-Alanine aminotransferase (ALT) <= 1.5 (SqrRoot) ULN

-Aspartate aminotransferase (AST) <= 1.5 (SqrRoot) ULN

- Participants serologically positive for human immunodeficiency virus (HIV) must:

--be on effective anti-retroviral therapy for at least 4 weeks; and

--have undetectable viral load; and

--have the CD4 count >=200 cells/microL; and

--have no reported opportunistic infections or Castleman s disease within 12 months prior to study treatment initiation

- Participants serologically positive for Hepatitis C virus (HCV) or Hepatitis B virus (HCB) must have an undetectable viral load.

- Women of child-bearing potential (WOCBP) must agree to use a highly effective method of contraception (hormonal, intrauterine device (IUD), surgical sterilization, abstinence) for the duration of the study treatment and up to 2 months after the last dose of PRGN-2009 and an effective method of contraception (barrier, hormonal, intrauterine device (IUD), surgical sterilization, abstinence) for 14 months after the last dose of cisplatin/docetaxel. Note: WOCBP is defined as any woman who has experienced menarche and has not had a hysterectomy or bilateral oophorectomy or is not postmenopausal (amenorrheic 12 months or more following cessation of exogenous hormonal treatments; if <50 years old and need follicle stimulating hormone [FSH] in the post-menopausal range).

Men must agree to use an effective method of contraception (barrier, surgical sterilization, abstinence) for the duration of the study treatment and up to 11 months after the last dose of the study drug(s). We also will recommend men on treatment with PRGN-2009 with female partners of childbearing potential ask female partners to be on highly effective birth control (hormonal, intrauterine device (IUD), surgical sterilization) during PRGN-2009 treatment and 2 months after that.

- Breastfeeding participants must be willing to discontinue breastfeeding from study treatment initiation through 2 months after the last dose of the study drug(s).

- Participants must have a tumor site that is amenable to biopsy and be willing to undergo pre- treatment biopsy for research purposes.

- Participants must be willing to undergo pre-treatment PET/CT imaging study.

- The ability of a participant to understand and the willingness to sign a written informed consent document.


- Peripheral motor or sensory neuropathy > Grade 2 per Common Terminology Criteria for Adverse Events (CTCAE) v.5 at screening.

- Prior therapy with an investigational drug, live vaccine, chemotherapy, immunotherapy, or any prior radiotherapy (except for palliative bone-directed therapy) within 4 weeks prior to the first study drug administration. Note: Participants may continue adjuvant hormonal therapy in the setting of a definitively treated cancer (e.g., breast).

- Prior therapy with any medications or substances that are moderate or strong inducers or moderate or strong inhibitors of cytochrome P450 (CYP3A),table3-3,table5-2 within 2 weeks prior to the first study drug administration.

- History of allergic reactions attributed to compounds of similar chemical or biological composition to drugs used in the study.

- Systemic (intravenous or oral) glucocorticoid (except for physiologic doses of corticosteroids, i.e., <= the equivalent of prednisone 10 mg/day) or other immunosuppressors such as azathioprine or cyclosporin A within 1 week prior to study treatment initiation. Note: Glucocorticoids as premedication for contrast-enhanced studies are allowed.

- Prior malignancy active within the previous 2 years except for locally curable cancer that is currently considered cured and does not require an additional standard of care treatment, such as cutaneous basal or squamous cell carcinoma, superficial bladder cancer, or cervical carcinoma in situ, or an incidental histological finding of prostate cancer.

- Prior allogenic tissue/solid organ transplant.

- History of heart failure.

- Positive beta-human chorionic gonadotropin (beta-HCG) serum or urine pregnancy test performed in females of childbearing potential at screening.

- Uncontrolled intercurrent illness or medical condition(s) evaluated by medical history and physical exam or situations that are not stable (e.g., recent hospitalization, Emergency Room visit or undergoing medication changes) that would potentially increase risk for the participant.

--Back to Top--


Not Provided

--Back to Top--


Principal Investigator

Referral Contact

For more information:

Clint T. Allen, M.D.
National Cancer Institute (NCI)
(301) 402-4216

Melissa Missy L. Wheatley
National Cancer Institute (NCI)
(240) 858-3391

NCI Referral Office
National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office

Clinical Trials Number:


--Back to Top--